Halozyme abandons cancer R&D as lead drug failedUS biotech Halozyme has been forced to cut more than half its workforce and exit cancer R&D after Share XHalozyme abandons cancer R&D as lead drug failedhttps://pharmaphorum.com/news/halozyme-abandons-cancer-rd-as-lead-drug-failed/